Puma Biotechnology | PBYI - Current Assets


Puma Biotechnology reported $143.58M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Daiichi Sankyo JPY 2.38T 150.33B Sep/2026
Exelixis USD 1.32B 70.8M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Moderna USD 7.34B 1.53B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Takeda JPY 3T 153.11B Sep/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026